Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

KITTEE TRC20 Token Ad

ADMP - Adamis Pharmaceuticals Corporation Stock Trading


home / stock / admp

Adamis Pharmaceuticals Corporation(NASDAQ: ADMP) stock trading description contact officers and directors.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a publicly traded OTC: ADMP biopharmaceutical company combining specialty pharmaceuticals and biotechnology products to create a variety of treatment options in the areas of oncology cancer , immunology, infectious diseases viruses , as well as allergic and respiratory conditions. Adamis is built on a business model that entails licensing innovative programs from companies or institutions and then advancing these initiatives through clinical development, regulatory approvals, and marketing. In order to efficiently accomplish its objectives, the Company operates through two subsidiaries Adamis Laboratories specialty pharmaceuticals and Adamis Therapeutics biotechnology . This structure permits each division to complement one other by providing a combination of pharmaceutical revenue and biotechnology blockbuster potential. The specialty pharmaceutical division will provide revenue to support the development of the Company s therapeutic products.
Stock Information

Adamis Pharmaceuticals Corporation Company Name:

ADMP Stock Symbol:

NASDAQ Market:

Adamis Pharmaceuticals Corporation Website:

MENU
ADMP ADMP Quote ADMP Short ADMP News ADMP Articles ADMP Message Board
Get ADMP Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Connect Twitter with Market Wire News
RECENT ADMP NEWS
  • ADMP - Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inf...

  • ADMP - Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

    SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an inve...

  • ADMP - What to Look For in a Penny Stock in 2022

    3 Things to Look For to Find Penny Stocks to Buy Right Now If you’re looking for penny stocks to buy, there are hundreds of stocks to choose from each day. But with so many stocks to pick from, how can you know which stocks are the best penny stocks to buy ? There are a few t...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Telegram

Join us on Telegram

Join the Trending Stocks News on Telegram to get immediate news notifications!

Telegram


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2022 Market Wire News